Health Care • Biotechnology: Pharmaceutical Preparations
$28.82 ▼ -1.60
(-5.26%)
MKT CAP: $576.7M • VOL: 310.0K
52W L $16 52W H $44
NGNE // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $925.0K | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$103.3M | -$82.6M | -$55.6M |
| Operating Margin % | — | -80.0% | — |
| Net Income (GAAP) | -$90.4M | -$75.1M | -$36.3M |
| EBITDA (Normalized) | -$102.4M | -$82.0M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$77.2M | -$70.6M | -$51.4M |
| Capital Expenditures (CapEx) | $1.2M | $808.0K | — |
| Free Cash Flow (FCF) | -$78.4M | -$71.4M | -$51.4M |
| FCF Margin % | — | -80.0% | — |
| Return on Invested Capital (ROIC %) | -45.0% | -37.6% | — |
| Cash & Short-Term Equivalents | $103.8M | $136.6M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $264.9M | $310.4M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR NGNE.